PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.
Phase 2
Completed
- Conditions
- Breast Neoplasms
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2008-11-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64
- Registration Number
- NCT00078000
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Boston, Massachusetts, United States
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
Phase 2
Completed
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2007-01-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT00077987
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 106
- Registration Number
- NCT00077974
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Madison, Wisconsin, United States
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 174
- Registration Number
- NCT00076024
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Sheffield, Yorkshire, United Kingdom
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
Phase 2
Completed
- Conditions
- Kidney Neoplasms
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT00076011
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Hannover, Germany
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
- First Posted Date
- 2004-01-08
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 361
- Registration Number
- NCT00075218
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Newcastle-Upon-Tyne, United Kingdom
Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India
Phase 2
Completed
- Conditions
- PLASMODIUM FALCIPARUM MALARIA
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 230
- Registration Number
- NCT00074841
- Locations
- ๐ฎ๐ณ
Pfizer Investigational Site, Indore, India
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
Phase 1
Completed
- Conditions
- Lung Neoplasms
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2006-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 87
- Registration Number
- NCT00074854
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Smyrna, Tennessee, United States
Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer
Phase 2
Completed
- Conditions
- Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2006-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00074867
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Quebec, Canada
Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Lymphoma, B-Cell
- Interventions
- Drug: Inotuzumab ozogamicin [CMC-544]
- First Posted Date
- 2003-12-05
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT00073749
- Locations
- ๐ฉ๐ช
Universitaet Muenchen Klinikum Grosshadern, Muenchen, Germany
๐บ๐ธNorthwestern Memorial Hospital, Chicago, Illinois, United States
๐บ๐ธUAB CCC Clinical Studies Unit, Birmingham, Alabama, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath